Lexington’s Cyteir Therapeutics to Close Two Years After IPO
A Lexington-based biotech firm, Cyteir Therapeutics Inc., has declared its plan to disband a mere two years following its public debut via an IPO. The company’s announcement on Friday included intends to cease the development of its solitary drug, a clinical-stage program designed to treat ovarian and other solid-tumor cancers. Cyteir aims to liquidate its…